Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Evolent Health, Inc Class A Common Stock (NY:EVH)

4.930 +0.130 (+2.71%)
Delayed Quote Updated: 10:06 AM EST, Nov 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Evolent Health, Inc Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
Analyst Expectations for Evolent Health's Future ↗
 
Via Benzinga
News headline image
Why Daktronics Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
Shares of Daktronics, Inc. (NASDAQ: DAKT) moved lower during Tuesday’s session following weak quarterly results. 
Via Benzinga
News headline image
Are You A Trader Or Investor: Biotech Momentum Is Picking Up ↗
ETFs have not helped as portfolio fillers but they can identify trends. We should play this rally out of a biotech bear market. 
Via Talk Markets
Topics ETFs
News headline image
Expedia Group, Gartner, Cloudflare, Cardinal Health And Other Big Stocks Moving Higher On Friday ↗
U.S. stocks traded higher, with the Dow Jones gaining around 200 points on Friday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
News headline image
Evolent Health (EVH) Q3 2023 Earnings Call Transcript ↗
EVH earnings call for the period ending September 30, 2023. 
Via The Motley Fool
Topics Earnings
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For October 16, 2023 ↗
 
Via Benzinga
News headline image
30 US States Pause Medicaid Disenrollment Due To Technical Glitch ↗
The U.S. 
Via Benzinga
News headline image
Evolent Health (EVH) Q2 2023 Earnings Call Transcript ↗
EVH earnings call for the period ending June 30, 2023. 
Via The Motley Fool
News headline image
Earnings Outlook For Evolent Health ↗
 
Via Benzinga
News headline image
Analyst Ratings for Evolent Health ↗
 
Via Benzinga
Growing Number of Industries Realize the Urgency for Ransomware Protection
EQNX::TICKER_START (NASDAQ:HCTI),(NASDAQ:HCAT),(NYSE:EVH),(NASDAQ:DH),(NASDAQ:NXGN) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Market Mixes It Up With A Broad Rally ↗
Biotech stocks remain sluggish but the longer-term outlook for breakthrough therapies - gene therapy, obesity, CNS, RNA - remain positive. 
Via Talk Markets
News headline image
Evolent Health (EVH) Q1 2023 Earnings Call Transcript ↗
EVH earnings call for the period ending March 31, 2023. 
Via The Motley Fool
News headline image
Recap: Evolent Health Q1 Earnings ↗
 
Via Benzinga
News headline image
Evolent Health (EVH) Q4 2022 Earnings Call Transcript ↗
EVH earnings call for the period ending December 31, 2022. 
Via The Motley Fool
News headline image
Cowen & Co. Maintains Outperform Rating for Evolent Health: Here's What You Need To Know ↗
 
Via Benzinga
News headline image
Why Evolent Health Stock Is Soaring Today ↗
Investors are applauding Evolent's latest acquisition. 
Via The Motley Fool
News headline image
Small & Mid Cap Life Science Stock Portfolio: Some Good Picks In A Stalled Sector ↗
A pivotal week looks to be shaping up with the usual macro concerns arising, such as a Fed meeting and big earnings waiting just around the corner. One possible path to help navigate around these macro... 
Via Talk Markets
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For April 12, 2023 ↗
 
Via Benzinga
5 Analysts Have This to Say About Evolent Health ↗
 
Via Benzinga
News headline image
Biotech And Life Science Trades: Q1 2023 Performance By The Numbers ↗
Despite a strong month and a great finish to the quarter, many traders remain cautious about the market. It’s been a volatile time after the collapse of Silicon Valley Bank, but the first quarter of... 
Via Talk Markets
News headline image
Evolent Health Q4 Top-Line Beats Expectation, Analyst Points To Visible Growth Outlook ↗
 
Via Benzinga
News headline image
SMID Cap Life Science Update: Are You An Investor Or Trader? ↗
Despite choppy trading, there is an upward tilt to life science stocks since the 9/26/22 lows. 
Via Talk Markets
News headline image
When Small Cap Biotechs Lose Momentum: Are You An Investor Or A Trader? ↗
A few small cap biotechs lost momentum last week so now might be the time to take profits. But many of these stocks are favored because of their core technology and favored by funds; time to buy? 
Via Talk Markets
News headline image
Foot Locker, Ross Stores, Palo Alto Networks, And Other Big Gainers From Friday ↗
U.S. stocks closed higher on Friday, with the Dow Jones gaining around 200 points. Here is the list of some big stocks recording gains in the previous session. 
Via Benzinga
News headline image
Why InMed Pharmaceuticals Shares Tumbled 28%; Here Are 67 Biggest Movers From Friday ↗
Gainers AGBA Group Holding Limited (NASDAQ: AGBA) gained 50.7% to close at $6.78 on Friday. 
Via Benzinga
News headline image
This Analyst Is Bullish On Evolent Health's Recent Deal, Calls 'Highly Strategic Acquisition' ↗
 
Via Benzinga
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
News headline image
Why PaxMedica Shares Are Trading Higher By Over 53%? Here Are 47 Stocks Moving In Friday's Mid-Day Session ↗
Gainers PaxMedica, Inc. (NASDAQ: PXMD) gained 53.5% to $2.38 after the company announced an equity investment agreement for up to $20 million with Lincoln Park Capital. 
Via Benzinga
News headline image
Centene Agrees To Divest Magellan Specialty Health To Evolent Health ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.